Gene · 11065
Papers2,651
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 2,651
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| ResNet50 and Single-Cell Multi-Omics analysis identify key cellular and molecular features in pediatric acute lymphoblastic leukemia. | Ann Hematol | 2025 | 41125957 | PubTator, text mining | PubMed |
| UBE2C promotes cell cycle progression and suppresses DNA damage-induced apoptosis in triple-negative breast cancer. | DNA Repair (Amst) | 2025 | 41086596 | PubTator, text mining | PubMed |
| Inhibitory Effects of Hesperetin and EGCG in the Lung Cancer Progression involves impairment in TOP2A gene expression regulation. | Appl Biochem Biotechnol | 2025 | 41074927 | PubTator, text mining | PubMed |
| HKI-357 inhibits castration-resistant prostate cancer by targeting UBE2C via the AKT signaling pathway. | Biochem Pharmacol | 2025 | 41067287 | PubTator, text mining | PubMed |
| Development of a novel 4-protein signature for prognostic prediction in hepatitis B virus-induced hepatocellular carcinoma. | Discov Oncol | 2025 | 41060497 | PubTator, text mining | PubMed |
| A signature of correlated CDC20 and UBCH10 expression indicates poor prognosis in primary head and neck squamous cell carcinoma. | BMC Cancer | 2025 | 41029491 | PubTator, text mining | PubMed |
Tumor microenvironment delineates differential responders to trastuzumab emtansine in HER2-positive metastatic breast cancer patients previously treated with pyrotinib: an exploratory biomarker analysis of a phase II study (NJMU-BC02). | Signal Transduct Target Ther | 2025 | 41016944 | PubTator, text mining | PubMed |
| Investigating Germ Cell Transition Genes in Breast Cancer: Exploring the Genesis of Cancer Testis-Associated Markers. | Int J Mol Sci | 2025 | 41009526 | PubTator, text mining | PubMed |
| Integrated multi-omics analysis reveals PTM networks as key regulators of colorectal cancer progression and immune evasion. | Discov Oncol | 2025 | 41003898 | PubTator, text mining | PubMed |
| [Expression of Concern] Lentivirus-mediated RNA interference targeting UbcH10 reduces cell growth and invasion of human osteosarcoma cells via inhibition of Ki-67 and matrix metalloproteinases. | Oncol Lett | 2025 | 40963524 | PubTator, text mining | PubMed |
| Machine Learning-Based Diagnostic Model for Accurate Prediction of Breast Cancer Using Immunohistochemical Images. | Cancer Biother Radiopharm | 2025 | 40938330 | PubTator, text mining | PubMed |
| Deciphering the molecular landscape of acute myeloid leukemia initiation and relapse: a systems biology approach. | Med Oncol | 2025 | 40928707 | PubTator, text mining | PubMed |
| CpG ODN Combined with Gold Nanorods Enhances Immune Activation and Its Potential Mechanism. | J Inflamm Res | 2025 | 40922946 | PubTator, text mining | PubMed |
| Single-cell transcriptomic landscape of sciatic nerve after transection injury. | J Neuroinflammation | 2025 | 40849669 | PubTator, text mining | PubMed |
| Oxidative stress in cancer: from tumor and microenvironment remodeling to therapeutic frontiers. | Mol Cancer | 2025 | 40847302 | PubTator, text mining | PubMed |
| Single-cell transcriptomic analysis reveals metastatic and immunosuppressive characteristics in meningioma brain-tumor interface. | J Transl Med | 2025 | 40826459 | PubTator, text mining | PubMed |
| UBE2C-mediated ubiquitination of ACSL4 inhibits ferroptosis and promotes gastric cancer progression. | Discov Oncol | 2025 | 40813933 | PubTator, text mining | PubMed |
| Long noncoding RNAs regulating enzymatic reactions in cancer. | Exp Mol Med | 2025 | 40804479 | PubTator, text mining | PubMed |
| Deficiency of the UBE2C/F264 Axis Underlies Intrinsic Radioresistance in Cervical Carcinoma. | J Proteome Res | 2025 | 40748296 | PubTator, text mining | PubMed |
| Inhibition of UBE2C Promotes Parkin-Mediated K63-Linked Ubiquitination of TOP2A to Induce Senescence and Increase Sensitivity of Doxorubicin in Breast Cancer. | Adv Sci (Weinh) | 2025 | 40729680 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/11065/papers?page=5